secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001437749-25-024720
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree reports positive istaroxime interim data in SCAI Stage C cardiogenic shock; plans global Phase 3
--------------------------------------------------------------------------------

- Interim analysis of first 20 patients in SEISMiC C Phase 2 study: no new safety signals, hemodynamic improvements consistent with prior trials.
- Istaroxime was added to existing inotropes/vasopressors; no excess arrhythmias observed despite greater illness severity.
- Company cites data as instrumental for moving istaroxime to a global Phase 3 program in heart failure and cardiogenic shock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774925024720/0001437749-25-024720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774925024720/wint20250805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer